Insights

As the global economic landscape continues to evolve, Vietnam, with its dynamic economic growth and increasingly optimized investment environment, has become a focal point for international investors. It is not only a hotbed for manufacturing but also an emerging hub for high-tech industries and services. However, opportunities are always accompanied by challenges. How to navigate steadily in Vietnam, seize investment opportunities, and mitigate potential risks is a critical issue every investor must address. Leadvisor Law Firm, in collaboration with its global member firm, Bizconsult Law Firm, is hosting an online seminar titled "Vietnam Investment Insights: Opportunities, Compliance, and Risk Management." This event aims to provide comprehensive legal services to both domestic and international investors, helping clients expand steadily in a complex and dynamic business environment. During this seminar, you will gain in-depth insights into Vietnam’s economic growth drivers, trade agreement advantages, and strategic business environment. Our team of experts will analyze the latest trends in the Vietnamese market, uncover investment opportunities in manufacturing, high-tech industries, and services, and delve into key topics such as market entry, legal structures, and tax compliance. Practical strategies for building a compliance framework will also be shared. A special interactive discussion session will allow you to engage directly with senior legal experts from Bizconsult Law Firm. Together, we will explore how to identify and address potential risks in Vietnam, including those related to politics, taxation, labor, and intellectual property. Additionally, we will discuss effective risk mitigation strategies to ensure your investments remain secure, compliant, and resilient in operation.

Amid the wave of globalization in business, Singapore has leveraged its unique business environment and status as a financial hub to offer unprecedented opportunities for Chinese entrepreneurs and investors. However, alongside these opportunities come a range of complex risks and challenges, with business and family disputes increasingly becoming focal points for investors. Renowned for its stable political environment, robust legal system, and open business climate, Singapore has attracted numerous family businesses and high-net-worth individuals seeking to invest or establish family offices. Yet, due to a lack of proactive planning or improper asset management, family businesses often face challenges such as asset division, management disputes, and even potential operational disruptions during the succession process. To assist family businesses, high-net-worth individuals, and investors in effectively addressing these challenges, Linklaters Law Firm, in collaboration with its Singapore member firm, WMH Law Corporation, is hosting a special online seminar on overseas investment titled **"Singapore Investment Risks and Entrepreneurial Family Wealth Succession"** on **November 8, 2024, at 2:00 PM**. We have invited seasoned legal experts, **Mark Lee** and **Sarah Yeo**, from WMH Law Corporation, a member of Linklaters Global, to join us online to discuss common corporate and family dispute cases in Singapore, along with strategies for dispute resolution. The seminar will explore how to devise preemptive plans to help you and your business respond swiftly and effectively to potential conflicts. Through these invaluable insights and strategies, you will be better equipped to mitigate risks and take appropriate measures when necessary, safeguarding your commercial interests and legal rights.

At this year's Euro PCR 2023, the results of two percutaneous renal artery denervation (RDN) studies from China were presented in the "Late Breaking Clinical Trail" session, which aroused heated debates in both academia and the industry: one of them is the "Pivotal Trial of Targeted Denervation for Hypertension" led by Professor Huo Yong of Peking University First Hospital and supported by Suzhou Xinmai Medical Device Co. (hereinafter referred to as "SMART Trial") led by Prof. Huo Yong from Peking University First Hospital and supported by Suzhou Xinmai Medical Devices Co. Ltd. (hereinafter referred to as "Miliweiye") supported the clinical trial "Effectiveness and Safety Study of Netrod-HTN Radiofrequency Denervation System". Both trials received considerable attention, and the results of the studies were positive, providing new evidence for the treatment of hypertension with RDN. The results were deemed positive because, based on the data reported by the investigators, both clinical trials met both the primary and secondary objectives of the study hypotheses. Based on the data reported by the two trials at the conference, on 29 June 2023, industry consultant CIC Consulting led the successful online live streaming of the "SMART Trial Results Interpretation Conference". The meeting was hosted by CIC Consulting, which provided an excellent sharing and interpretation of the differences between the two trials, from protocol design to clinical implementation to data collection, which are worth exploring and thinking about in depth.

Webinar Content: 1. What is private equity investment? 2. The main transaction process of equity investment and financing 3. Scope of legal due diligence 4. Transaction documents and their core terms

In recent years, the subfield of endovascular interventions has received a lot of attention with the rapid development of neurointerventions, cardiovascular interventions and cardiac electrophysiology. However, the field of hypertension, which has the largest number of patients in the field of cardiovascular disease, a heavy burden of disease on society, and a huge potential for improvement in disease diagnosis, treatment, and control, has not received the attention it deserves. In fact, in the field of device therapy for several major chronic diseases corresponding to the cardiopulmonary system, such as hypertension, asthma, chronic obstructive pulmonary disease, and early stage tumours of the lungs, China is still in the early stages of development, and so far there is no industry leading enterprise, and there is still a huge market potential yet to be developed. Against this background, on 14 January 2023, CIC Consultants officially released the "China Hypertension and Asthma Intervention Blue Book" (hereinafter referred to as the "Blue Book"), and on 18 January, the Blue Book Interpretation Meeting, hosted by CIC Consultants, was ceremoniously held online.

With the deepening understanding of human beings themselves, the medical frontiers of diagnosis (diagnosis) diagnosis and treatment of precision stem cell technology, medical artificial intelligence and other fields have shown remarkable therapeutic potential in diagnosis and treatment. These sub-sectors are also booming with the help of both capital and technology. Highlights of the CIC Consulting live broadcast: 1. How to see the broadening of application scenarios and incremental market opportunities brought by new technologies, and how to realize the diagnosis of different indications and the empowerment of the whole treatment field? 2. What are the capital and policy actions and support in the frontier areas of innovative technologies, artificial intelligence, and data-driven healthcare services? 3. What are the most cutting-edge technology routes in the respective segments? What kind of companies and teams can lead the industry trend, seize the dividends of technology and market, and stand out from the competition in the fast iterative progress of the innovative healthcare track?